Immunotherapy Treatments for Skin Cancer Boost Long-Term Survival Rates
0 citations
David R. Minor
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
113Publications signalées
11650Citations signalées
0Affiliations récentes
Domaines associés
Cancer Immunotherapy and BiomarkersMelanoma and MAPK PathwaysCAR-T cell therapy researchCutaneous Melanoma Detection and ManagementImmunotherapy and Immune Responses
Publications récentes
Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas
David R. Minor, Kevin B. Kim, R. Krishna Murthy Karuturi, Mohammed Kashani–Sabet
4 citationsFrontiers in Oncology
Data from A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey S. Weber, John A. Thompson, Omid Hamid, David R. Minor et autres
0 citations
Data from A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey S. Weber, John A. Thompson, Omid Hamid, David R. Minor et autres
0 citations
Supplementary Data from A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey S. Weber, John A. Thompson, Omid Hamid, David R. Minor et autres
0 citations
Supplementary Data from A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey S. Weber, John A. Thompson, Omid Hamid, David R. Minor et autres
0 citations
A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma
David R. Minor, Kevin B. Kim, Ricky T. Tong, Max C. Wu et autres
13 citationsCancer Biotherapy and Radiopharmaceuticals
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Ahmad A. Tarhini, Ni Kang, Sandra J. Lee, F. Stephen Hodi et autres
31 citationsJournal for ImmunoTherapy of Cancer
Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach
Kevin B. Kim, Liliana Soroceanu, David de Semir, Sherri Z. Millis et autres
38 citationsJournal of Investigative Dermatology
A Study Of Hepatic Internal Radiation with Yttrium90 Resin Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Uveal Melanoma Metastatic to the Liver
David R. Minor, Kevin B. Kim, Ricky T. Tong, Max C. Wu et autres
0 citationsSSRN Electronic Journal
312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition
Ahmad A. Tarhini, Ni Kang, F. Stephen Hodi, Gary I. Cohen et autres
1 citationRegular and Young Investigator Award Abstracts
Initial report of treatment of uveal melanoma with hepatic metastases with yttrium90 internal radiation followed by ipilimumab and nivolumab.
David R. Minor, Takami Sato, Marlana Orloff, Jason J. Luke et autres
7 citationsJournal of Clinical Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.